5Tonino RP, Meunier PJ, Emkey R, et al. Skeletal benefits of alendronate:7-year treatment of postmenopausal osteoporotic women. Phase Ⅲ Osteoporosis Treatment Study Group[J]. J Clin Endocrinol Metab,2000,85(9) :3109-3015.
6Adami S, Baroni MC, Broggini M, et al. Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin [J]. Osteoporos Int, 1993,3 ( Suppl 3 ) :S21- 27.
8Cao J,Venton L, Sakata T, et al. Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice[J].J Bone Miner Res,2003,18(2):270-277.
9Hofbauer LC, Gori F, Riggs BL, et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells:potential paracrine mechanisms of glucocorticoid-induced osteoporosis[J]. Endocrinology, 1999,140(10) :4382-4389.
10Frith JC,Rogers MJ. Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro[J]. J Bone Miner Res, 2003,18(2) :204-212.
